21st Century Oncology, Inc -- Moody's downgrades 21st Century Oncology to Caa2; outlook negative

New York, August 05, 2014 -- Moody's Investors Service downgraded 21st Century Oncology, Inc.'s ("21st Century") Corporate Family Rating to Caa2 from B3 and Probability of Default Rating to Caa2-PD from B3-PD. In a related action, Moody's downgraded the ratings on the company's $100 million revolving credit facility and $90 million term loan to B1, the rating on the company's existing $350 million 8.875% second lien notes to Caa2, and rating on the $380 million 9.875% subordinated notes to Caa3. The company's speculative grade liquidity rating was changed to SGL-4 and the rating outlook was changed to negative from stable.

Vollständigen Artikel bei Moodys lesen